Document:

Exhibit 10.17

 

GENOCEA BIOSCIENCES, INC.

 

CASH BONUS PROGRAM

FOR FISCAL YEARS 2012 AND 2013

 

This Cash Bonus Program (the “Bonus Program”) has been established by Genocea Biosciences, Inc. (the “Company”) to provide for cash bonus awards (each, a “Bonus”) for each of fiscal year 2012 and 2013 (each, a “Performance Period”) to certain executive officers and other key employees of the Company to promote and reward the achievement of key strategic business goals and individual performance goals.

 

The Bonus Program is administered by the Board of Directors of the Company (the “Board”) and its delegates.  The Board and its delegates, to the extent of such delegation, are referred to herein as the “Administrator”.  Any interpretation or decision by the Administrator with respect to the Bonus Program or any Bonus will be final and conclusive as to all persons.

 

Executive officers and other key employees of the Company and its subsidiaries are eligible to participate in the Bonus Program.  The Administrator will select, from among those eligible, the persons who will from time to time participate in the Bonus Program (each, a “Participant”).

 

The Administrator in its discretion shall establish the performance goals for each Performance Period and shall determine the extent to which such performance goals have been satisfied for a Performance Period based on its qualitative and quantitative assessment of performance.  Performance goals may include either individual or corporate goals, or both individual and corporate goals.  The weightings of the individual and corporate performance goals under the Bonus Program, to the extent applicable, shall be determined for each Participant and each Performance Period by the Administrator.

 

The Administrator shall determine a Participant’s target Bonus (the “Target”) for each Performance Period.  The Target will be expressed as a percentage of the Participant’s annual base salary.  The Administrator in its discretion may award a Bonus to a Participant in excess of 100% of the Target if the Administrator determines, in its discretion, that achievement of the performance goals during the applicable Performance Period exceeded the target level of performance and may, in its discretion, award a Bonus that is less than the Target if it determines, in its discretion, that achievement of performance goals was at a level less than such target level of performance.

 

The Administrator shall determine the amount of any Bonus to be paid hereunder based on the Administrator’s determination of the level of the achievement of the performance goals.  Except as otherwise determined by the Administrator, all payments under the Bonus Program will be made, if at all, not later than March 15th of the calendar year following the calendar year in which the Performance Period ends.  The Administrator may, but need not, provide that a Bonus payment will not be made unless the Participant has remained employed with the Company and its subsidiaries through the date of payment.

 

1

 

All payments under the Bonus Program will be subject to reduction for applicable tax and other legally or contractually required withholdings.

 

The Board may amend the Bonus Program at any time and from time to time.  The Board may at any time terminate the Bonus Program.

 

The Bonus Program will be effective for fiscal years 2012 and 2013.  The Bonus Program shall not be construed to require the adoption of a similar Bonus Program for future fiscal years.

 

2EXHIBIT 10.18

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.  REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

CONFIDENTIAL

 

Amendment No. 2 to Patent License Agreement 
 between the University of Washington and Genocea Biosciences, Inc.

 

This Amendment No. 2 is made and entered into as of September 12, 2012, by and between the University of Washington, a public institution of higher education and an agency of the State of Washington, acting through UW Center for Commercialization, Technology Licensing (“University”), and Genocea Biosciences, Inc., a Delaware corporation with its principal place of business at 100 Acorn Park Drive, 5th floor, Cambridge, MA 02140 (“Company”).  University and Company are referred to individually as a “Party” and collectively as the “Parties”.

 

WHEREAS, University and Company are Parties to a certain Patent License Agreement with an Effective Date of January 23, 2010, as amended by Amendment No. 1 dated July 19, 2012 (the “Agreement”);

 

WHEREAS, University and Company, through this Amendment No. 2, wish to update Section A3.5 “Financial Milestones” of the Agreement based on the outcome of ongoing research on antigenicity of the C-terminus of gD2 in the laboratory of Dr. David Koelle (the “Research”, as further described in Appendix A);

 

NOW, THEREFORE the Parties hereto agree as follows:

 

1.                                      Unless otherwise defined herein, capitalized terms used in this Amendment No. 2 have the meanings set forth in the Agreement.

 

2.                                      Milestone A3.5.1 in Section A3.5 is deleted in its entirety and replaced with the following:

 

[* * *]

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed by their respective authorized representatives.

 

	
University of Washington
    	
 
    	
Genocea   Biosciences, Inc.
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/   Angela Loihl
    	
 
    	
By:
    	
/s/   William D. Clark
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
Angela   Loihl
    	
 
    	
Name:
    	
William   D. Clark
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
Associate   Director
    	
 
    	
Title:
    	
President &   CEO
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
9/12/2012
    	
 
    	
Date:
    	
9/17/2012
    

 

1

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.  REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

CONFIDENTIAL

 

Appendix A

 

Research Summary

 

UW has IP pending in the US patent office concerning compositions of HSV-2 glycoprotein D, also called gD2, encoded by gene US6, for use as a vaccine to prevent or treat HSV-2 infections of humans.  The native gD2 is about 393 amino acids long.  Many previous candidate vaccines have synthesized AA 1-340 in eukaryotic cells; the C-terminal part was genetically deleted to improve manufacturing yield.  Further, the eukaryotic cells automatically cleave off AA 1-25 as a biologically inherent process during protein expression, yielding a final vaccine composition of AA 26-339.  The core discovery, published in PNAS in 2003, is that there is a 9 amino acid epitope in the C terminal domain, AA 365-373, that is recognized by human CD8 T-cells.  The discovery suggests that improved candidate gD2-based vaccines should contain the C-terminal domain.  These human CD8 T-cells are frozen in the lab and can be re-used for more experiments.  The US patent office is restricting allowed claims to relatively short sections of gD2.  UW C4C, UW-retained counsel, and a potential licensee see value in extending allowed claims to longer versions of gD2, containing both the discovered CD8 epitope at AA 365-373, and other more N-terminal regions which also have scientific rationale for inclusion.  Dr. Koelle will conduct the following work to develop supporting data for the filing of a new Licensed Patent covering longer versions of gD2.

 

In the proposed experiments, Dr. Koelle will consult with counsel and potential licensee to determine the AA composition (left and right ends) of interest.  Dr. Koelle will clone the relevant portions of gD2 DNA and sequence-confirm the correct clones.  Dr. Koelle will prepare prototype vaccines of various gD2 regions in a DNA vaccine format.  The lab will create human-like cell lines that are competent to interact with human CD8+ T-cells, as first published by our in 2001.  These cell lines will further be treated with the different candidate gD2 vaccine prototypes and appropriate positive and negative controls.  The expected result is that the CD8 T-cells specific for gD2 AA 365-373 will have intact and full recognition of longer pieces of gD2 and full length gD2, as long as they contain AA 365-373.  Thus, allowance of claims to proposed vaccines of various and longer lengths will be supported by experimental data.

 

2EXHIBIT 10.19

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.  REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

CONFIDENTIAL

 

Amendment No. 3 to Patent License Agreement 
 between 
 the University of Washington 
 and 
 Genocea Biosciences, Inc.

 

This Amendment No. 3 is made and entered into as of November 7, 2013, by and between the University of Washington, a public institution of higher education and an agency of the State of Washington, acting through UW Center for Commercialization, Technology Licensing (“University”), and Genocea Biosciences, Inc., a Delaware corporation with its principal place of business at 100 Acorn Park Drive, 5th floor, Cambridge, MA 02140 (“Company”).  University and Company are referred to individually as a “Party”, and collectively as the “Parties”.

 

WHEREAS, University and Company are Parties to a certain Patent License Agreement with an Effective Date of January 23, 2010, as amended by Amendments No. 1 and No. 2 (the “Agreement”);

 

WHEREAS, University and Company, through this Amendment No. 3, wish to amend certain financial terms of the Agreement;

 

NOW, THEREFORE the Parties hereto agree as follows:

 

1.                                      Unless otherwise defined herein, capitalized terms used in this Amendment No. 3 have the meanings set forth in the Agreement.

 

2.                                      Sections A3.7 and A3.8 of Appendix A are hereby deleted in their entirety and replaced as follows:

 

A3.7               Third Party Royalties.  If Company is required to pay royalties to a Third Party based on Company’s manufacture, use, or sale of Licensed Product subject to one or more patents of such Third Party then the royalties Company pays to University may be reduced by [* * *] of such royalties actually paid to the Third Party provided that use of any Third Party patent is required for such manufacture, use, or sale of Licensed Product, or Licensed Product is otherwise subject to a Third Party license, and provided that the royalty to the University shall not fall below [* * *].

 

A3.8               Sublicensing Consideration.  In addition to the running royalty payments due on Net Sales by any Sublicensee pursuant to Subsection A3.3 of this Exhibit A, Company shall pay to University a percentage of all Sublicensing Consideration received for a Sublicense according to the schedule below.  [* * *]  For the avoidance of doubt, any failure by Company 

 

1

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.  REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

CONFIDENTIAL

 

to pay University an amount under this Section A3.8 which is actively being disputed pursuant to Article 29 shall not be deemed a breach or default by Company of its obligations under this Agreement.

 

[* * *]

 

2

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.  REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

CONFIDENTIAL

 

IN WITNESS WHEREOF, the Parties have caused this Amendment No. 3 to be duly executed by their respective authorized representatives.

 

	
University of Washington
    	
 
    	
Genocea   Biosciences, Inc.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/   Fiona Willis
    	
 
    	
By:
    	
/s/   Robert E. Farrell Jr.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
Fiona   Willis, Ph.D, MBA
    	
 
    	
Name:
    	
Robert   E. Farrell Jr.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
Director   of Technology Licensing
    	
 
    	
Title:
    	
Vice   President of Finance and Administration
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
11/07/13
    	
 
    	
Date:
    	
11/6/2013
    

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}]]